Compare CWCO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | GYRE |
|---|---|---|
| Founded | 1973 | 2002 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 581.2M | 679.4M |
| IPO Year | 1997 | 2004 |
| Metric | CWCO | GYRE |
|---|---|---|
| Price | $33.78 | $7.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $40.00 | $17.00 |
| AVG Volume (30 Days) | ★ 111.6K | 52.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.14 | 0.02 |
| Revenue | ★ $132,073,368.00 | $275,000.00 |
| Revenue This Year | $4.34 | $19.88 |
| Revenue Next Year | $42.86 | N/A |
| P/E Ratio | ★ $29.61 | $372.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.69 | $6.58 |
| 52 Week High | $39.12 | $11.77 |
| Indicator | CWCO | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 51.60 |
| Support Level | $32.78 | $7.25 |
| Resistance Level | $34.39 | $7.91 |
| Average True Range (ATR) | 0.99 | 0.26 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 45.59 | 52.14 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.